Joshua K. Sabari, MD, discusses updated results from the phase 1 CHRYSALIS trial examining amivantamab in patients with non–small cell lung cancer whose tumors harbored EGFR exon 19 deletion or L858R mutations.
Joshua K. Sabari, MD, an assistant professor in the Department of Medicine at NYU Langone Health’s Perlmutter Cancer Center, discusses updated results from the phase 1 CHRYSALIS trial examining amivantamab (JNJ-61186372) in patients with non–small cell lung cancer (NSCLC) whose tumors harbored EGFR exon 19 deletion or L858R mutations.
Data from the trial were presented during the 2020 ESMO Virtual Congress and demonstrated promising results with this approach in a heavily pretreated patient population, according to Sabari. These patients had cMET- and C7S-mediated resistance and achieved a response rate of 43.5% with amivantamab in combination with lazertinib, says Sabari. Patients with treatment-naive disease who had exon 19 deletions and patients with exon 21 insertion mutations and were treated with the combination experienced a response rate of 100%, adds Sabari.
During the 2021 World Conference on Lung Cancer, the updated results from the cohort of patients with exon 20 insertion mutations were presented. In these patients, the an objective response rate of 40%, a clinical benefit rate of 74%, and a median duration of response of 11.1 months, says Sabari. Additionally, there was a median progression-free survival of 8.3 months. These updated results have the potential to be practice-changing and may be a valuable step forward for this patient